Skip to main content

Table 4 Total QALYs, total costs, and incremental cost-effectiveness ratios for scenarios 2, 4, 6 and 8a

From: Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model

Scenario Quadrivalent vs No vaccination Bivalent vs No vaccination Bivalent vs Quadrivalent
∆QALYs ∆COSTS ICER ∆QALYs ∆COSTS ICER ∆QALYs ∆COSTS ICER
Scenario
 2: Both vaccines = 8.5 US$;
 2-dose scheme - FX 6.3
4,395 −805.7 US$ cost-saving 4,486 −735.9 VEF cost- saving 91 69.8 VEF 0.77
 4: Both vaccines = 8.5 US$;
 2-dose scheme - FX: 170
−106.4 US$ cost- saving −36.6 VEF cost- saving 69.8 VEF 0.77
 6: BV: 8.5 US$ QV: 13.79 US$;
 2-dose scheme - FX 6.3
−788.9 US$ cost- saving −735.9 VEF cost- saving 53.0 VEF 0.58
 8: BV: 8.5 US$ QV: 13.79 US$;
 2-dose scheme - FX: 170
345.5 US$ 0.08 −36.6 VEF cost-saving −382.1 VEF cost-saving
  1. Notes: Results for a cohort of 264,489 women (discount = 5%)
  2. Abbreviations: FX exchange rate (VEF per US$), QV quadrivalent, BV bivalent. GDP per capita: 104,404 VEF. [68] (See scenarios 1, 3, 5, 7 in Additional file 1: Table S2), QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio, VEF Venezuelan bolívar fuerte, US$ United States dollar
  3. aCosts and ICERs are expressed in millions of VEF, 2015